🔥🐔 BizChicken 🐔🔥

Companies Similar to ADMA Biologics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

AnaptysBio, Inc.

AnaptysBio, Inc. logo
Market Cap: Medium
Employees: Low

Imsidolimab, Rosnilimab, ANB032

Anaptys Bio, Inc. is a clinical stage biotechnology company focused on developing therapeutic product candidates for inflammation and immuno-oncology indications. Their products target dermatological inflammatory diseases and other human inflammatory conditions.

Tags: antibody development, biotechnology, immuno-oncology, inflammation, therapeutics

Symbol: ANAB

Recent Price: $13.22

Industry: Biotechnology

CEO: Mr. Daniel R. Faga

Sector: Healthcare

Employees: 117

Address: 10770 Wateridge Circle, San Diego, CA 92121-5801

Phone: 858 362 6295

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

HCW Biologics Inc.

HCW Biologics Inc. logo
Market Cap: Lowest
Employees: Lowest

HCW9218

HCW Biologics Inc. is a preclinical stage biopharmaceutical company that develops novel immunotherapies for chronic, low-grade inflammation and age-related diseases. Their lead products target various cancers, auto-immune, and metabolic diseases.

Tags: auto-immune diseases, biopharmaceutical, cancer, chronic inflammation, immunotherapy

Symbol: HCWB

Recent Price: $0.43

Industry: Biotechnology

CEO: Dr. Hing C. Wong Ph.D.

Sector: Healthcare

Employees: 45

Address: 2929 North Commerce Parkway, Miramar, FL 33025

Phone: 954 842 2024

Last updated: 2024-12-31

Absci Corporation

Absci Corporation logo
Market Cap: Medium
Employees: Low

Integrated Drug Creation Platform

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using an integrated drug creation platform for partners in the United States. Its platform enables the creation of biologics by unifying the drug discovery and cell line development processes.

Tags: AI, biologics, cell line development, drug discovery, pharmaceuticals

Symbol: ABSI

Recent Price: $2.65

Industry: Biotechnology

CEO: Mr. Sean McClain

Sector: Healthcare

Employees: 155

Address: 18105 SE Mill Plain Boulevard, Vancouver, WA 98683

Phone: 360 949 1041

Last updated: 2024-12-31

Abivax SA American Depositary Shares

Abivax SA American Depositary Shares logo
Market Cap: Medium
Employees: Lowest

obefazimod

ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.

Tags: biotechnology, chronic inflammatory diseases, clinical trials, immune response, ulcerative colitis

Symbol: ABVX

Recent Price: $7.05

Industry: Biotechnology

CEO: Mr. Marc M. P. de Garidel M.B.A.

Sector: Healthcare

Employees: 62

Address: 7-11 boulevard Haussmann, Paris, null 75009

Phone: 33 1 53 83 09 63

Leadership

  • Marc de Garidel, MBA, Chief Executive Officer
  • Didier Blondel, EVP, Chief Financial Officer & Board Secretary
  • Fabio Cataldi, MD, Chief Medical Officer
  • Ida Hatoum, Chief People Officer, Chief Compliance Officer
  • David Zhang, PhD, Chief Strategy Officer
  • Pierre Courteille, Pharmacist, MBA, Chief Business Officer
  • Didier Scherrer, PhD, Chief Scientific Officer
  • Jérôme Denis, PhD, EVP, Process Development & Manufacturing
  • Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
  • Sylvie Grégoire, PharmD, Chair of the Board
  • Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
  • Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
  • June Lee, MD FACCP, Venture Partner at 5AM Ventures
  • Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
  • Troy Ignelzi, CFO of Rapport Therapeutics
  • Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
  • Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
  • Hema Keshava, Senior Vice President, Finance
  • Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
  • Patrick Malloy, Senior Vice President, Investor Relations
  • Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
  • Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
  • Kevin Shan, PhD, Vice President, Global Head of Biometrics
  • Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
  • Ana Sharma, MPH, Vice President, Global Head of Quality
  • Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture

Last updated: 2024-12-31

Adicet Bio, Inc.

Adicet Bio, Inc. logo
Market Cap: Low
Employees: Low

ADI-001

Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.

Tags: allogeneic treatments, biotechnology, cancer therapy, gamma delta T cell, immunotherapy

Symbol: ACET

Recent Price: $0.90

Industry: Biotechnology

CEO: Mr. Chen Schor BA, CPA, M.B.A.

Sector: Healthcare

Employees: 143

Address: 200 Clarendon Street, Boston, MA 02116

Phone: 650 503 9095

Last updated: 2024-12-31

ADMA Biologics, Inc.

ADMA Biologics, Inc. logo
Market Cap: High
Employees: Medium

BIVIGAM, ASCENIV, Nabi-HB

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases.

Tags: biologics, biopharmaceutical, immunodeficiency, infectious diseases, plasma-derived

Symbol: ADMA

Recent Price: $17.49

Industry: Biotechnology

CEO: Mr. Adam S. Grossman

Sector: Healthcare

Employees: 624

Address: 465 State Route 17, Ramsey, NJ 07446

Phone: 201 478 5552

Leadership

  • Adam S. Grossman, Founder, Director, President, & Chief Executive Officer
  • Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President of Compliance
  • Brad Tade, Chief Financial Officer & Treasurer
  • Doug Chambers, Vice President, Quality
  • Daniel Garcia, Vice President, IgG Product Management
  • Jeffrey Janek, Vice President, Production Operations
  • Michael Least, Vice President, Market Access & National Accounts
  • Drew Pantello, Vice President, Marketing & Corporate Development
  • Cindy Petersen, Vice President, Human Resources
  • Michael Space, Vice President, Long Range Planning & Analysis
  • Shane Stremming, Vice President, Operations for ADMA BioCenters
  • Jeffrey Gruenglas, Executive Director, Government Affairs, Health Policy & Scientific Communications
  • John Hafl, Executive Director, Sales
  • Sheri Klostermeyer, Executive Director, Supply Chain
  • Steven A. Elms, Chairman
  • Jerrold B. Grossman, D.P.S., Founder & Vice Chairman
  • Alison C. Finger, Director
  • Bryant E. Fong, Director
  • Lawrence P. Guiheen, Director
  • Young T. Kwon, PhD, Director

Last updated: 2024-12-31

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. logo
Market Cap: Low
Employees: Low

ADVM-022

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing gene therapy product candidates for the treatment of ocular and rare diseases. Their lead product, ADVM-022, targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema.

Tags: ADVM-022, biotechnology, gene therapy, ocular diseases, rare diseases

Symbol: ADVM

Recent Price: $4.69

Industry: Biotechnology

CEO: Dr. Laurent Fischer

Sector: Healthcare

Employees: 121

Address: 800 Saginaw Drive, Redwood City, CA 94063

Phone: 650 656 9323

Last updated: 2024-12-31

Arvinas, Inc.

Arvinas, Inc. logo
Market Cap: High
Employees: Medium

Bavdegalutamide, ARV-471, ARV-766

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is based in New Haven, Connecticut and collaborates with organizations like Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG.

Tags: PROTAC, biopharmaceutical, cancer therapy, clinical-stage, protein degrader

Symbol: ARVN

Recent Price: $19.00

Industry: Biotechnology

CEO: Dr. John G. Houston Ph.D.

Sector: Healthcare

Employees: 445

Address: 5 Science Park, New Haven, CT 06511

Phone: 203 535 1456

Leadership

  • John G. Houston, Ph.D., Chairperson, Chief Executive Officer, and President
  • Noah Berkowitz, M.D., Ph.D., Chief Medical Officer
  • Angela M. Cacace, Ph.D., Chief Scientific Officer
  • Jared Freedberg, J.D., General Counsel and Corporate Secretary
  • Paul McInulty, Senior Vice President, Regulatory Affairs
  • John Northcott, Chief Commercial Officer
  • Kelly Page, Senior Vice President, Global Head of Oncology Strategy and Program Leadership
  • Andrew Saik, Chief Financial Officer
  • Lisa Sinclair, Senior Vice President, Corporate Operations
  • Ian Taylor, Ph.D., President, R&D
  • Randy Teel, Ph.D., Chief Business Officer
  • Steve Weiss, Senior Vice President, Chief Human Resources Officer

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Biomerica, Inc.

Biomerica, Inc. logo
Market Cap: Lowest
Employees: Low

diagnostic and therapeutic products

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for medical conditions and diseases worldwide, focusing on gastrointestinal diseases, food intolerances, and diabetes.

Tags: biomedical, diabetes, diagnostic, food intolerances, gastrointestinal, therapeutic

Symbol: BMRA

Recent Price: $0.31

Industry: Medical - Devices

CEO: Mr. Zackary S. Irani

Sector: Healthcare

Employees: 64

Address: 17571 Von Karman Avenue, Irvine, CA 92614

Phone: 949 645 2111

Last updated: 2024-12-31

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

IGALMI

Bio Xcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence for developing transformative medicines in neuroscience and immuno-oncology. It focuses on re-innovating existing drugs with machine learning to identify new therapeutic uses.

Tags: agitation treatment, artificial intelligence, biopharmaceutical, clinical trials, immuno-oncology, neuroscience

Symbol: BTAI

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Vimal D. Mehta Ph.D.

Sector: Healthcare

Employees: 74

Address: 555 Long Wharf Drive, New Haven, CT 06511

Phone: 475 238 6837

Last updated: 2024-12-31

ChromaDex Corporation

ChromaDex Corporation logo
Market Cap: Low
Employees: Low

NIAGEN, TRU NIAGEN, IMMULINA

Chroma Dex Corporation is a bioscience company focused on healthy aging, offering consumer products, ingredient technologies, and analytical reference standards. It specializes in NAD+ research and commercializes NAD+ precursor nicotinamide riboside (NIAGEN) and immune-supporting compounds.

Tags: NAD+, NIAGEN, bioscience, dietary supplements, healthy aging, immune support

Symbol: CDXC

Recent Price: $5.45

Industry: Biotechnology

CEO: Mr. Robert N. Fried

Sector: Healthcare

Employees: 106

Address: 10900 Wilshire Boulevard, Los Angeles, CA 90024

Phone: 310 388 6706

Last updated: 2024-12-31

GRI Bio, Inc.

GRI Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

GRI-0621, GRI-0803, GRI-0124, GRI-0729, ADAIR, ADMIR

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of inflammatory, fibrotic, and autoimmune diseases in the United States, with a diverse pipeline including treatments for idiopathic pulmonary fibrosis and systematic lupus erythematosus.

Tags: autoimmune diseases, biopharmaceutical, clinical-stage, fibrotic diseases, inflammatory diseases

Symbol: GRI

Recent Price: $0.80

Industry: Biotechnology

CEO: Ms. Cristina Gil White

Sector: Healthcare

Employees: 4

Address: 2223 Avenida de la Playa, LA Jolla, CA 92037

Phone: 619 400 1170

Last updated: 2024-12-31

IGM Biosciences, Inc.

IGM Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

IGM-2323

IGM Biosciences, Inc. is a biotechnology company focused on developing Immunoglobulin M (Ig M) antibodies for treating cancer, infectious diseases, and autoimmune and inflammatory diseases. Their lead product candidate, IGM-2323, is in Phase 2 clinical trials for B cell Non-Hodgkin's lymphoma.

Tags: antibodies, biotechnology, cancer, clinical trials, pharmaceutical

Symbol: IGMS

Recent Price: $6.05

Industry: Biotechnology

CEO: Ms. Mary Beth Harler M.D.

Sector: Healthcare

Employees: 204

Address: 325 East Middlefield Road, Mountain View, CA 94043

Phone: 650 965 7873

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

MediciNova, Inc.

MediciNova, Inc. logo
Market Cap: Low
Employees: Lowest

MN-166 (ibudilast)

Medici Nova, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious diseases with unmet medical needs, including neurologic disorders, fibrotic diseases, and solid tumor cancers.

Tags: United States, biopharmaceutical, fibrotic diseases, neurological disorders, novel therapeutics, solid tumors, unmet medical needs

Symbol: MNOV

Recent Price: $2.11

Industry: Biotechnology

CEO: Dr. Yuichi Iwaki M.D., Ph.D.

Sector: Healthcare

Employees: 13

Address: 4275 Executive Square, La Jolla, CA 92037

Phone: 858 373 1500

Leadership

  • Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer, and Founder
  • Kazuko Matsuda, M.D., Ph.D, MPH, Chief Medical Officer
  • David H. Crean, Ph.D., Chief Business Officer
  • Jason J. Kruger, CPA (inactive), Chief Financial Officer
  • Hideki Nagao, Member of the Board of Directors
  • Carolyn Beaver, Member of the Board of Directors
  • Nicole Lemerond, CFA, Member of the Board of Directors

Last updated: 2024-12-31

NexImmune, Inc.

NexImmune, Inc. logo
Market Cap: Lowest
Employees: Lowest

Artificial Immune Modulation

Nex Immune, Inc., a clinical-stage biotechnology company, develops therapies for cancer and immune-mediated diseases using its Artificial Immune Modulation platform. The company is advancing cell therapy candidates including NEXI-001, NEXI-002, and NEXI-003.

Tags: T cell immunotherapies, biotechnology, cancer, cell therapy, immune-mediated diseases, nanoparticle technology

Symbol: NEXI

Recent Price: $0.15

Industry: Biotechnology

CEO: Mr. John Trainer M.B.A.

Sector: Healthcare

Employees: 6

Address: 9119 Gaither Road, Gaithersburg, MD 20877

Phone: 301 825 9810

Leadership

  • Kristi Jones, Chief Executive Officer
  • Mathias Oelke, Ph.D., Chief Scientific Officer
  • Daniel Bednarik Ph.D., Senior Vice President, Molecular Engineering & Protein Design
  • Jack Ragheb, Senior Vice President, Translational Science
  • Tonya Catterton, Vice President, Quality & Compliance
  • Tim Stover, Vice President, Corporate Controller
  • Karen Haslbeck, Head, Human Resources
  • Matt Schiller, Head, Business Development

Last updated: 2024-12-31

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation logo
Market Cap: Medium
Employees: Medium

immunoSEQ

Adaptive Biotechnologies Corporation is a commercial-stage company that develops an immune medicine platform for diagnosing and treating various diseases, including COVID-19 and lymphoid cancers.

Tags: COVID-19, cancer, diagnostics, immune medicine, immunosequencing, translational research

Symbol: ADPT

Recent Price: $6.11

Industry: Biotechnology

CEO: Mr. Chad M. Robins M.B.A.

Sector: Healthcare

Employees: 709

Address: 1165 Eastlake Avenue East, Seattle, WA 98109

Phone: 206 659 0067

Last updated: 2024-12-31

Avid Bioservices, Inc.

Avid Bioservices, Inc. logo
Market Cap: Medium
Employees: Medium

Biopharmaceutical Manufacturing Services

Avid Bioservices, Inc., a contract development and manufacturing organization, offers process development and CGMP manufacturing services for biopharmaceutical drug substances derived from mammalian cell culture, serving the biotechnology and biopharmaceutical industries.

Tags: CGMP, biopharmaceutical, manufacturing, monoclonal antibodies, process development, recombinant proteins

Symbol: CDMO

Recent Price: $12.33

Industry: Biotechnology

CEO: Mr. Nicholas Stewart Green B.Sc., MBA

Sector: Healthcare

Employees: 371

Address: 2642 Michelle Drive, Tustin, CA 92780

Phone: 714 508 6100

Last updated: 2024-12-31